Published in Toxins (Basel) on October 19, 2012
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev (2017) 0.87
Targeting botulinum A cellular toxicity: a prodrug approach. J Med Chem (2013) 0.86
Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery. Expert Rev Mol Diagn (2014) 0.85
Botulinum Toxin as a Pain Killer: Players and Actions in Antinociception. Toxins (Basel) (2015) 0.84
Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. J Infect Dis (2016) 0.84
AbobotulinumtoxinA: A 25-Year History. Aesthet Surg J (2017) 0.82
A label free colorimetric assay for the detection of active botulinum neurotoxin type A by SNAP-25 conjugated colloidal gold. Toxins (Basel) (2013) 0.80
Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment. Toxins (Basel) (2015) 0.79
Endomicroscopy and electromyography of neuromuscular junctions in situ. Ann Clin Transl Neurol (2014) 0.78
Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism. Curr Top Med Chem (2014) 0.77
Botulinum Neurotoxin Type A in Neurology: Update. Neurol Int (2015) 0.77
Acrylamide inhibits nerve sprouting induced by botulinum toxin type A. Neural Regen Res (2014) 0.76
A Heterologous Reporter Defines the Role of the Tetanus Toxin Interchain Disulfide in Light-Chain Translocation. Infect Immun (2015) 0.76
SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons. Neurotox Res (2015) 0.76
Effective Botulinum Toxin Injection Guide for Treatment of Temporal Headache. Toxins (Basel) (2016) 0.76
Isolation and quantification of botulinum neurotoxin from complex matrices using the BoTest matrix assays. J Vis Exp (2014) 0.75
Extraocular Muscles Tension, Tonus, and Proprioception in Infantile Strabismus: Role of the Oculomotor System in the Pathogenesis of Infantile Strabismus-Review of the Literature. Scientifica (Cairo) (2016) 0.75
Phosphatase Inhibitors Function as Novel, Broad Spectrum Botulinum Neurotoxin Antagonists in Mouse and Human Embryonic Stem Cell-Derived Motor Neuron-Based Assays. PLoS One (2015) 0.75
Comparison of Effects of Botulinum Toxin Injection Between Subacute and Chronic Stroke Patients: A Pilot Study. Medicine (Baltimore) (2016) 0.75
Botulinum Toxin in Pediatric Neurology: Switching Lanes From Death to Life. Glob Pediatr Health (2015) 0.75
Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors. Sci Rep (2015) 0.75
[Use of botulinum toxin in strabismus]. Ophthalmologe (2016) 0.75
SNAREs--engines for membrane fusion. Nat Rev Mol Cell Biol (2006) 12.74
SV2 is the protein receptor for botulinum neurotoxin A. Science (2006) 4.51
Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc (1981) 4.31
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia (2010) 4.24
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia (2010) 3.54
Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol (1994) 3.04
Structure and function of SNARE and SNARE-interacting proteins. Q Rev Biophys (2005) 3.01
Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol (2008) 2.98
Pharmacologic weakening of extraocular muscles. Invest Ophthalmol (1973) 2.82
Substrate recognition strategy for botulinum neurotoxin serotype A. Nature (2004) 2.81
Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology (2009) 2.63
Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem (1994) 2.59
Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology (1987) 2.38
OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache (2011) 2.31
The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis. Inflammopharmacology (2010) 2.11
Regulated airway goblet cell mucin secretion. Annu Rev Physiol (2008) 1.97
Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol (2012) 1.88
Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol (2003) 1.81
Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry (2004) 1.79
Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg (2006) 1.79
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol (2007) 1.78
Clinical spectrum of botulism. Muscle Nerve (1998) 1.74
Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell (2008) 1.66
Basic immunological aspects of botulinum toxin therapy. Mov Disord (2004) 1.62
Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences. Exp Neurol (1997) 1.61
Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol (2007) 1.60
Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J Neurochem (1999) 1.58
Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem (1994) 1.57
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord (2005) 1.54
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology (2003) 1.50
European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol (2004) 1.49
Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins. Trends Neurosci (2005) 1.49
Improvement of wound healing after hemorrhoidectomy: a double-blind, randomized study of botulinum toxin injection. Dis Colon Rectum (2005) 1.48
Molecular mechanisms of platelet exocytosis: role of SNAP-23 and syntaxin 2 in dense core granule release. Blood (2000) 1.47
Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care (2007) 1.43
Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci U S A (2006) 1.41
Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry (2009) 1.41
Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep (2007) 1.40
Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem (2007) 1.39
Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins. J Biol Chem (2005) 1.37
Botulinum toxin injections for cervical dystonia. Neurology (1990) 1.37
Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus (1980) 1.37
Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology (2005) 1.34
Mechanism of substrate recognition by botulinum neurotoxin serotype A. J Biol Chem (2007) 1.30
Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci U S A (2004) 1.29
Cell entry strategy of clostridial neurotoxins. J Neurochem (2009) 1.29
Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog (2007) 1.28
Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. Biochemistry (1994) 1.27
Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog (2011) 1.24
Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Ann N Y Acad Sci (1994) 1.23
The t-SNARE syntaxin 4 is regulated during macrophage activation to function in membrane traffic and cytokine secretion. Curr Biol (2003) 1.22
Involvement of SNAP-23 and syntaxin 6 in human neutrophil exocytosis. Blood (2000) 1.21
Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology (2006) 1.20
Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev (2005) 1.18
Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study. Mayo Clin Proc (2006) 1.17
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology (1999) 1.17
SNAP-23 is not cleaved by botulinum neurotoxin E and can replace SNAP-25 in the process of insulin secretion. J Biol Chem (1997) 1.17
Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem (2002) 1.17
Treatment of cervical dystonia with botulinum toxin. Mov Disord (2004) 1.15
Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J Cell Biol (2007) 1.15
The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. J Oral Maxillofac Surg (1999) 1.12
Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology (2001) 1.11
Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb Pathog (1998) 1.11
Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol (2011) 1.11
Drooling and its management in cerebral palsy. Dev Med Child Neurol (1987) 1.08
Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes. Clin J Pain (2003) 1.07
A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain (2003) 1.06
Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J Neurosci (2002) 1.05
The current use of botulinum toxin. J Clin Neurosci (2000) 1.04
Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition. Biochemistry (2005) 1.02
Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity. Biochemistry (2006) 1.02
Is the light chain subcellular localization an important factor in botulinum toxin duration of action? Mov Disord (2004) 1.01
Receptor and substrate interactions of clostridial neurotoxins. Toxicon (2009) 1.01
Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol (2010) 1.00
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol (2006) 1.00
Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design. Biochemistry (2005) 1.00
A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J Biol Chem (2010) 0.99
Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol (2010) 0.99
Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics. Neurotox Res (2006) 0.98
Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J Cell Sci (2012) 0.96
Botulinum toxin treatment of adult spasticity : a benefit-risk assessment. Drug Saf (2006) 0.96
Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity. Protein J (2008) 0.96
Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord (2005) 0.96
Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review. Clin Rehabil (2006) 0.96
Unlabeled uses of botulinum toxins: a review, part 2. Am J Health Syst Pharm (2006) 0.96
Engineering botulinum neurotoxin to extend therapeutic intervention. Proc Natl Acad Sci U S A (2009) 0.95
Treatment of chronic low back pain with successive injections of botulinum toxin a over 6 months: a prospective trial of 60 patients. Clin J Pain (2006) 0.95
Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci U S A (2010) 0.94
Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F. Nat Struct Mol Biol (2009) 0.94
Botulinum toxin therapy for cervical dystonia. Neurotox Res (2006) 0.94
Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel. Toxicon (2008) 0.94
Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol (1999) 0.93
Engineered toxins: new therapeutics. Toxicon (2009) 0.92
A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors (2000) 0.92
Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity. Biochemistry (2007) 0.92
Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25. J Biol Chem (2011) 0.91
Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev (2005) 0.90
Different response of the knockout mice lacking b-series gangliosides against botulinum and tetanus toxins. Biochim Biophys Acta (2005) 0.90